🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

SBRT (6*6Gy) is a new treatment option for small oral cavity cancers (T1-2) at risk of local recurrence after resection (R1, PNI..): Julian Biau reports the STEREOPOSTOP GORTEC 2017-03. Convenient Fast Similar outcomes than post op brachy Mostly VMAT homogeneous plans #ESTRO25

Exciting to see data from STAR-TREC - higher rates of organ preservation with long course chemoRT vs short course RT for rectal cancer

STORM-PEACE V trial reported by Thomas Zilli #ESTRO25 Pelvic ENI superior to MDT for pelvic relapses after local Tx for #prostate cancer (6mo ADT each) Improves Biochemical PFS Locoregional PFS MFS ADT free survival Tox NS ENI clear SOC Online The Lancet Oncology Cc Piet Ost

We are delighted to announce that Dr. Ibrahim Abu-Gheida will be speaking at the Breast Cancer session during the #bestofastro gulf and the 7th Annual Conference of #SARO.

Online: Association between risk-reducing surgeries and survival in young BRCA carriers with #breastcancer: an international cohort study thelancet.com/journals/lanon…

🎉 We’re excited to share that The 7th SARO Annual Meeting & 2nd Best of ASTRO Gulf, has been officially granted #24_CME hours by the Saudi Commission for Health Specialties. 📍 This year’s event will be held on-site at Hilton, Jeddah, on May 15-17, 2025, providing the perfect

يبدأ غدا المؤتمر السنوي السابع للجمعية السعودية لطب الأورام الإشعاعي بالتزامن مع مؤتمر best of ASTRO الخليجي الثاني في جدة، بحضور ١٢٢ متحدث ومدير جلسة من ١٥ دولة حول العالم و يشمل ٢٨ جلسة علمية و ١٠٠ محاضرة تقريبا وورشة عمل في فندق الهليتون ١٦-١٧ مايو حياكم الله 🌺 للتسجيل

That’s a wrap on Best of ASTRO – Gulf 2025! An incredible gathering of experts, ideas, and collaboration. Thank you to all our speakers, attendees, and partners for making this event a success. Here’s to continued innovation in radiation oncology — together, we shape the future.

Great catching up with American University of Beirut VP and #Dean of Faculty of Medicine , MD Anderson Cancer Center and world class Neurosurgeon Alumni Relations Office at AUB #AbuDhabi Proudly #AUBite and grateful Dr. Fadlo Khuri Ali Taher

Pleasure visiting our friend Tamer Refaat, MD PhD MSCI at Loyola University Chicago #CancerCenter during our ASCO trip. Great work being done over there & our commitment to excellence will make collaboration happen Lamiaa Abdallah Burjeel Holdings Prof.Dr.Humaid Al-Shamsi 🇦🇪 Emirates Oncology Society Emirates Medical Association 🇦🇪 🇺🇸 #ASCO2025

Thank you Tamer Refaat, MD PhD MSCI for hosting us! It was a pleasure meeting Dr Kavadi CEO ASTRO along with oncology leaders from 🇪🇬 and Ofcourse our good friend Mohamed Abazeed, MD, PhD from Northwestern Medicine discussing future promising collaboration needed ☢️ 🌍 🌎 Prof.Dr.Humaid Al-Shamsi 🇦🇪 Emirates Oncology Society

A pleasure to meet in person great #RadOncs #Medtwitter Ibrahim Abu-Gheida Steven H. Lin This is #ASCO25 ASCO Prof.Dr.Humaid Al-Shamsi 🇦🇪 Mohammed Rafiullah Khan

It was great catching up with wonderful people from my #Almamater at #ASCO25 Steven H. Lin Sana Sukhun - د.سناء السخن Nagi El Saghir MD, FASCO, FACP Prof.Dr.Humaid Al-Shamsi 🇦🇪 MD Anderson Cancer Center American University of Beirut Medical Center

#ASCO25 #SRS Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial. | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… Lucas Caussa ☢️

SHARE trial - partial breast irradiation with twice-daily fractionation - no difference in cosmesis - few recurrence at 5-year median FU - APBI better any G2+ and worse breast G2+ toxicity #ASCO25 OncoAlert #OncoAlert #BreastCancer #radonc

Wonderful #BreastCancer #De-escalation session by Icro Meattini ASCO #ASCO25 Emirates Oncology Society Aydah AlAwadhi, MD 🇦🇪 Prof.Dr.Humaid Al-Shamsi 🇦🇪

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? NRG Oncology ASTRO #BreastCancer nejm.org/doi/full/10.10…

With all due respect, I don't think this is a good interpretation of the NSABP-B51 trial. Thanks for the authors for this huge work, as this is clearly very difficult data to obtain. However, it should be acknowledged that there are too many shortcomings and caveats that it

What a pleasure was at #ASCO25 to meet my graduated students & colleagues now prominent oncologists worldwide Raafat Alameddine Rita Assi Ibrahim Abu-Gheida Katia Khoury Imane El-Dika Charbel Matar with Deborah Mukherji & Ali Shamseddine #Chicago ASCO American University of Beirut

Metastasis-directed therapy improves outcomes in oligometastatic #ProstateCancer in #WOLVERINE study. Chad Tang, MD MD Anderson Cancer Center sits down with Leslie Ballas Cedars-Sinai to discuss a meta-analysis of STOMP, ORIOLE, ARTO, EXTEND & COMET-SABR trials on oligometastatic